Application of FDA adverse event report data to the surveillance of dietary botanical supplements

Annals of Pharmacotherapy

Volumn 42, Issue 5, 2008, Pages 653-660

  Wallace, Robert B ^a   Gryzlak, Brian M ^a   Zimmerman, M Bridget ^a   Nisly, Nicole L ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alternative medicine; Dietary supplements; Herbal medicine; MedWatch; Pharmacoepidemiology

Indexed keywords

ECHINACEA EXTRACT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYPERICUM PERFORATUM EXTRACT; PEPPERMINT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; AMNESIA; ANEMIA; ARTICLE; ASTIGMATISM; BACKACHE; BLEEDING; BLINDNESS; BLURRED VISION; BRAIN DISEASE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONCENTRATION LOSS; CONFUSION; CONJUNCTIVA DISEASE; COUGHING; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPHAGIA; DYSPNEA; EPISTAXIS; FAINTNESS; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENITAL SYSTEM DISEASE; GINGIVITIS; GRAND MAL SEIZURE; HEART ARRHYTHMIA; HEART PALPITATION; HEMATEMESIS; HEMATOMA; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFORMATION PROCESSING; INTERNATIONAL NORMALIZED RATIO; ISCHEMIA; LABORATORY TEST; LEG CRAMP; LETHARGY; LIMB DISEASE; LIMB TREMOR; LIVER FAILURE; LIVER FUNCTION TEST; LYMPHOCYTOSIS; MIXED MULLERIAN TUMOR; MOUTH DISEASE; MULTIPLE ORGAN FAILURE; MUSCLE CONTRACTION; NAUSEA; NECK PAIN; PANCREATITIS; PARESTHESIA; PARTIAL THROMBOPLASTIN TIME; PATIENT INFORMATION; PELVIS PAIN SYNDROME; PERNICIOUS ANEMIA; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; PSORIASIS; QT PROLONGATION; RECTUM HEMORRHAGE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SPINAL PAIN; SPONTANEOUS ABORTION; SPOTTING; STOMACH DISCOMFORT; SUBDURAL HEMATOMA; SUICIDE; TACHYCARDIA; THORAX PAIN; THROAT DISEASE; THROMBOCYTOPENIA; TONGUE SWELLING; TONIC CLONIC SEIZURE; TUMOR; UNITED STATES; VAGINA DISEASE; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING; WALKING DIFFICULTY; WEAKNESS; WOUND HEALING IMPAIRMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DIETARY SUPPLEMENTS; ECHINACEA; GARLIC; GINKGO BILOBA; HYPERICUM; MENTHA PIPERITA; PANAX; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 42949176072     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K611     Document Type: Article

References (47)

1. Ernst E. Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 2004;13:767-71.
2. General Accounting Office. Improvements needed in overseeing the safety of dietary supplements and "functional foods." GAO/RCED-00-156. Washington, DC: General Accounting Office, 2000.
3. Onel S. Dietary supplements: a definition that is black, white, and gray. Am J Law Med 2005;31:341-8.
4. Dietary Supplement Health and Education Act of 1994. PL. 103-417.
5. Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005;27:1847-58.
6. Top-selling medicinal herbs in the U.S., 1999-2003. World almanac and book of facts. World Almanac Education Group Inc., New York, 2005.
7. Department of Health and Human Services, Office of Inspector General. Adverse event reporting for dietary supplements: an inadequate safety valve. Washington, DC: Department of Health and Human Services, 2001.
8. Hathcock J. Dietary supplements: how they are used and regulated. J Nutr 2001;131(suppl):1114S-7S.
9. Larsen LL, Berry JA. The regulation of dietary supplements. J Am Acad Nurse Pract 2003;15:410-4.
10. Noonan C, Noonan WP. Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients. Toxicology 2006;221:4-8.
11. Taylor CL. Regulatory frameworks for functional foods and dietary supplements. Nutr Rev 2004;62:55-9.
12. Milan F, Fallek R. Current regulations of dietary supplements: DSHEA revisited. Alternative Therapies Women's Health 2003;5:92-5.
13. Dietary Supplement and Nonprescription Drug Consumer Protection Act. 2006; P.L. 109-462.
14. De Smet PAGM. Herbal medicine in Europe: relaxing regulatory standards. N Engl J Med 2005;352:1176-8.
15. Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J European Union 2004;L136:85-90.
16. Medicines and Healthcare Products Regulatory Agency. Qualified persons. www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE& nodeId=680 (accessed 2006 Jan 19).
17. Medicines and Healthcare Products Regulatory Agency. Follow up of adverse reactions. www.mhra.gov.uk/home/idcplg?IdcService=SS_ GET_PAGE&nodeId=685 (accessed 2006 Jan 19).
18. Medicines and Healthcare Products Regulatory Agency. What should be included in a report. www.mhra.gov.uk/home/idcplg?IdcService=SS_ GET_PAGE&nodeId=5 (accessed 2006 Jan 19).
19. Nestmann ER, Harwood M, Martyres S. An innovative model for regulating supplement products: natural health products in Canada. Toxicology 2006;221:50-8.
20. Watson WA, Litovitz TL, Rodgers GC Jr., et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005;23:589-666.
21. Litovitz T. The TESS database. Use in product safety assessment. Drug Saf 1998;18:9-19.
22. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269:2765-8.
23. Bren L. FDA's response to food, dietary supplement, and cosmetic adverse events. FDA Consum 2003;(July-August):12-3.
24. Mosquera M. FDA tracks the bad stuff. Government Computer News: www.gcn.com/23_8/news/25613-1.html (accessed 2006 Jan 16).
25. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997;157:913-9.
26. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
27. Huntley AL, Thompson Coon J, Ernst E. The safety of herbal medicinal products derived from echinacea species: a systematic review. Drug Saf 2005;28:387-400.
28. Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. Am J Psychiatry 2005;162:189-91.
29. Fraunfelder FW. Ocular side effects associated with dietary supplements and herbal medicines. Drugs Today (Barc) 2005;41:537-45.
30. Haller CA, Meier KH, Olson KR. Seizures reported in association with use of dietary supplements. J Toxicol Clin Toxicol 2005;43:23-30.
31. Pipe A. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. Clin J Sports Med 2004;14:188-9.
32. Maglione M, Miotto K, Iguchi M, Hilton L, Shekelle P. Psychiatric symptoms associated with ephedra use. Expert Opin Drug Saf 2005;4: 879-84.
33. US FDA, Center for Food Safety and Applied Nutrition. FDA/CFSAN SN/ AEMS removed, www.cfsan.fda.gov/~dms/aems.html (accessed 2006 Jan 6).
34. Kennedy D, Goldman S, Lillie R. Spontaneous reporting in the United States. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York: John Wiley & Sons, 2000:149-74.
35. Kingston R. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements. Thromb Res 2005;117:137-44.
36. Mantle D, Wilkins RM, Gok MA. Comparison of antioxidant activity in commercial Ginkgo biloba preparations. J Altern Complement Med 2003;9:625-9.
37. Los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. John's Wort. Am J Health Syst Pharm 2002;59: 545-7.
38. Garrard J, Harms S, Eberly LE, Matiak A. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 2003; 163:2290-5.
39. Palmer ME, Haller C, McKinney PE, et al. Adverse events associated with dietary supplements: an observational study. Lancet 2003;361:101-6.
40. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr., et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002;20:391-452.
41. De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004;76:1-17.
42. Busse JW, Heaton G, Wilson KR, Mills EJ. Disclosure of natural product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clin Proc 2005;80:616-23.
43. Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 2004;12:90-8.
44. Institute of Medicine, National Research Council. Dietary supplements: a framework for evaluating safety. Washington, DC: National Academies Press, 2004.
45. Ahmad SR, Goetsch RA, Marks NS. Spontaneous reporting in the United States. In: Strom BL, ed. Pharmacoepidemiology. 4 ed. West Sussex, England: John Wiley & Sons, Ltd; 2005:131-59.
46. Dwyer JT, Holden J, Andrews K, et al. Measuring vitamins and minerals in dietary supplements for nutritional studies. Anal Bioanal Chem 2007;389:37-46.
47. Dwyer JT, Picciano MF, Betz JM, et al. Progress in development of an integrated dietary supplement ingredient database at the NIH Office of Dietary Supplements. J Food Composition Anal 2006;19(suppl): S108-14.